Darzalex 400mg/20ml injection

Darzalex 400mg/20ml Injection (Daratumumab)

Darzalex 400mg/20ml Injection (Daratumumab) is an advanced immunotherapy for treating multiple myeloma. This form of cancer affects plasma cells in the bone marrow. The medicine binds to the CD38 protein on myeloma cells. As a result, it activates the immune system to destroy these harmful cells.

Doctors often prescribe Darzalex for patients with relapsed or treatment-resistant multiple myeloma. Moreover, it is frequently combined with other drugs such as lenalidomide, bortezomib, or dexamethasone. These combinations have shown to improve treatment outcomes and extend progression-free survival.

Key Information

• Strength: 400mg per 20ml vial
• Formulation: Intravenous infusion solution
• Active Ingredient: Daratumumab
• Indication: Relapsed or refractory multiple myeloma

Usage Instructions

Each vial contains a single-use dose. A healthcare provider administers it through intravenous infusion. To reduce side effects, patients are premedicated with corticosteroids, antipyretics, and antihistamines. This helps lower the risk of infusion reactions such as chills or fever.

Your doctor will set a dosing schedule that suits your treatment plan. Initially, Darzalex is given weekly. Over time, it may shift to bi-weekly or monthly infusions for maintenance.

Storage Instructions

Store the vial in a refrigerator between 2°C and 8°C. Do not freeze or shake it. Additionally, protect it from light and keep out of children’s reach.